Abramson Cancer Center, University of Pennsylvania, The Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania 19104, USA.
J Natl Compr Canc Netw. 2012 Apr;10(4):558-63. doi: 10.6004/jnccn.2012.0053.
Testicular cancer is the most common cancer in men in their 20s and 30s, and has been considered a model of a curable neoplasm. The longer life expectancy of testicular cancer survivors makes minimizing the long-term health issues related to hypogonadism particularly important, and because testicular cancer affects men mostly in their reproductive years, infertility can also be a major concern. Hypogonadism, infertility, and testicular cancer have been associated with one another. These associations suggest the existence of common etiologic factors, including improper testicular development during fetal life. The effect of cancer treatment on testosterone, luteinizing hormone, and follicle-stimulating hormone levels, and on fertility and overall paternity rates among testicular cancer survivors, are potentially significant issues. As the biologic mechanisms underlying hypogonadism, infertility, and testicular cancer become clearer, more research is needed to provide clinicians with evidence-based guidelines for the management of testicular cancer survivors.
睾丸癌是 20 至 30 岁男性中最常见的癌症，一直被视为可治愈肿瘤的典范。睾丸癌幸存者的预期寿命延长，使得将与性腺功能减退相关的长期健康问题最小化变得尤为重要，而且由于睾丸癌主要影响生殖期的男性，因此不育也可能是一个主要问题。性腺功能减退、不育和睾丸癌相互关联。这些关联表明存在共同的病因因素，包括胎儿期睾丸发育不当。癌症治疗对睾丸癌幸存者的睾酮、促黄体生成素和卵泡刺激素水平、生育能力和总体父亲率的影响，是潜在的重要问题。随着导致性腺功能减退、不育和睾丸癌的生物学机制变得更加清晰，需要开展更多的研究，以便为临床医生提供基于证据的睾丸癌幸存者管理指南。
